R1 RCM vs. Duet

What the largest end-to-end RCM outsourcer does well — and the governance question that multi-year percentage-of-collections contracts cannot answer

Published by Duet  ·  Independent  ·  No vendor relationship with R1 RCM  ·  April 2026

What R1 RCM Is — And Why It Runs Billions in Collections

R1 RCM (formerly NYSE: RCM, privatized by TowerBrook and Clayton, Dubilier & Rice in 2024) is the largest end-to-end revenue cycle management outsourcer in the United States. The company manages the complete revenue cycle for more than 100 health systems, processing billions of dollars in patient collections annually. Marquee clients include Ascension and LifePoint Health.

R1 is not a software vendor. R1 is an operations company — they take over your revenue cycle end to end, employ the specialists, run the workflow, integrate the technology, and take a percentage of what they collect. The business model, at scale, is genuinely powerful for health systems that want to convert fixed RCM operating costs into a variable, performance-linked expense.

In 2024, R1 acquired Acclara to strengthen its mid-revenue cycle coding capabilities and partnered with Palantir to deploy advanced analytics across its platform. These are real investments in real capability. Any CFO evaluating R1 should start from the acknowledgment that the underlying operations are serious and the client roster is real.

The question this article addresses is not: “Is R1 good at revenue cycle operations?” The question is: “Can R1 be the independent party that tells your CFO whether R1 is worth the percentage it is taking?”

What R1 Does Well — A Candid Assessment

1.  End-to-End Operational Scale

R1 can take a struggling revenue cycle operation and install a mature, multi-specialty RCM operating model in months, not years. For health systems with significant operational dysfunction, staff turnover, or technology debt, the alternative — fixing the problem internally — can take 2–4 years and millions in consulting fees. R1 compresses that timeline dramatically.

2.  Specialist Depth

R1 employs some of the most experienced denial management, prior authorization, and complex claims specialists in the country. At the individual case level, R1's specialists are often more skilled than the specialists a mid-size health system can afford to hire and retain. This is a real capability advantage that shows up in specific case resolution rates.

3.  Payer Intelligence

R1's scale — processing collections across 100+ health systems — gives the company pattern-recognition advantages on payer behavior that no individual health system can replicate. When a payer changes its denial patterns, R1 sees the change across its portfolio weeks before any individual client would notice. This intelligence is genuinely valuable.

4.  Variable-Cost Model

The percentage-of-collections model aligns R1's economic incentives with collection performance. When collections go up, R1 earns more. For CFOs struggling with fixed RCM cost structures that do not flex with volume, this variable-cost model is operationally attractive.

Where R1's Business Model Creates a Structural Accountability Problem

1.  The Percentage-of-Collections Conflict

R1 charges 3–8% of net collections, depending on the engagement scope. At a $500M net revenue health system, that is $15–40M annually in vendor fees. R1 earns more when collections go up. R1 earns more when they can attribute that improvement to R1's own interventions. R1 has a direct financial incentive to make the attribution as favorable to themselves as possible.

And R1 measures that attribution with R1's own analytics tool. This is not fraud. It is the arithmetic of percentage-of-collections business models. Any company whose fees scale with the performance they are measuring has a structural incentive to measure that performance favorably. This is exactly why external auditors exist for financial statements — and why external accountability exists for every other high-stakes financial relationship in an organization.

2.  The Multi-Year Lock-In

R1 contracts typically run 5–7 years, with transition costs that make early termination financially prohibitive for most health systems. By year three, the internal team that would have managed the revenue cycle has been displaced — reassigned, reorganized, or simply let go. The capability to run the RCM function internally no longer exists.

The CFO's ability to exit the R1 relationship depends not just on the contract terms, but on whether the health system has retained any independent capability to measure R1's performance. Most R1 clients have not. By year three of a seven-year contract, R1 is typically the only party with the data and the tooling to evaluate R1's own performance.

3.  The Displaced Internal Team Problem

When R1 takes over a revenue cycle, the internal team that previously managed it is typically reduced or dissolved. This is part of the cost-savings case. But it also means that when R1's performance is in question — year three, four, five into the relationship — there is no independent internal capability to produce a counter-assessment.

The CFO becomes dependent on R1's analytics, R1's benchmarks, and R1's attribution logic to evaluate R1. This dependency is not accidental. It is a predictable consequence of outsourcing the revenue cycle to a single vendor on a long-term percentage-of-collections contract.

4.  The Attribution Problem at Scale

Revenue cycle performance changes are driven by many variables simultaneously: payer behavior, case mix, coding practices, regulatory environment, Medicare Advantage enrollment growth, and macroeconomic factors. R1 routinely attributes revenue improvements to R1's interventions without controlling for these confounding variables.

A health system whose collections improved by 4% in 2024 — during a year when industry-wide Medicare Advantage denial patterns shifted and commercial payer mix trends improved — will see R1 claim credit for the improvement. The CFO has no independent way to decompose how much of that 4% was R1's operational improvement and how much was market factors.

Five Questions Every CFO Should Ask R1 Before the Next Renewal

1. Show me the complete attribution methodology R1 uses to claim credit for revenue cycle improvements — every variable controlled for, every benchmark source, every weighting factor. Who independently verified this methodology?
2. What percentage of the collections improvement since R1 took over is attributable to R1's specific interventions, versus market factors, payer mix changes, and case mix shifts we would have seen regardless?
3. If we terminated the R1 contract today and brought the revenue cycle back in-house, what is your estimate of the collection performance we would retain? Please provide the methodology behind your answer.
4. The R1 contract charges X% of net collections. What is R1's gross margin on our account? How does that margin compare to R1's portfolio average?
5. Who at R1 is accountable to our CFO — not our Revenue Cycle Director — for validated, third-party-auditable performance data? Can we schedule a quarterly CFO-level review that includes non-R1-sourced data?

How Duet Works With R1 Engagements — Not Against Them

Duet is not an R1 alternative. Health systems that have made a strategic decision to outsource their revenue cycle to R1 should not unwind that decision on the basis of this article. The operational and staffing case for R1 is separate from the governance case for independent accountability.

What a Duet engagement produces for an R1 client is the thing R1 cannot produce for itself: an independent CFO-level assessment of R1's attributable performance, benchmarked against non-R1 data, with transparent methodology the CFO can defend to a board audit committee.

The output of a Duet CLR on an R1 engagement is one of three things: (1) confirmation that R1's attributable performance justifies the percentage being charged, which gives the CFO the evidence to defend the R1 relationship at the board level; (2) evidence of an attribution gap, which gives the CFO the specific data needed to renegotiate the R1 contract terms or adjust the collection percentage; or (3) identification of performance gaps R1 is not addressing, which gives the health system a roadmap for scope adjustment, contract remedies, or (in extreme cases) transition planning.

All three outcomes are worth $25,000 on a multi-year, multi-million-dollar R1 engagement.

Verdict